BioSpace News Archive

AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal diseases, announced the completion of site initiation visits and the addition of five new clinical trial sites in Ukraine for the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced results for the second quarter ended June 30, 2021 and provided a business update.

MoonLake Immunotherapeutics AG today announced the appointment of Mr. Sturge as Chairman.

Verrica Pharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2021.

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the first 10 evaluable patients in the ongoing Phase IIa open label study with vilobelimab in Pyoderma Gangraenosum (PG).

Harmony Biosciences Holdings, Inc. and Blackstone (NYSE: BX) today announced that they have entered into a strategic financing collaboration where funds managed by Blackstone have agreed to provide Harmony with up to $330 million of financing and growth capital.

Vallon Pharmaceuticals, Inc. today reported its financial results for the quarter ended June 30, 2021.

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report second quarter 2021 financial results on Friday, August 13, 2021, prior to the market open.

Timber Pharmaceuticals, Inc. today provided a business update and announced financial results for the second quarter ended June 30, 2021.

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the second of two Phase 3 (ESSENCE-2) studies, evaluating the investigational drug CyclASol® to treat the signs and symptoms of dry eye disease DED, has been completely enrolled with a total of 834 participants.